Study of Molecular Characterisation of Early Operable Primary Breast Cancer in Pakistani Population

Launched by LIAQUAT UNIVERSITY OF MEDICAL & HEALTH SCIENCES · Feb 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the unique biological features of early-stage breast cancer in women from Pakistan. Researchers want to learn more about how these characteristics may affect treatment options and outcomes for patients. The study uses a method called immunohistochemistry (IHC) to analyze tissue samples from tumors, which helps in understanding the disease better.

To participate in this study, women must have a confirmed diagnosis of breast cancer and provide good quality tumor samples for analysis. However, those who have received chemotherapy or radiation therapy before surgery are not eligible. If you qualify and choose to participate, you can expect to provide a tumor sample and contribute to important research that aims to improve breast cancer treatment for women in your community. The trial is currently recruiting participants, so there is an opportunity to get involved and help advance our understanding of this disease.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women with confirmed diagnosis of breast cancer without history of taking neoadjuvant therapy Good quality tumour samples available for IHC
• Exclusion Criteria:
• • patients received pre-operative chemotherapy or radiotherapy